PaxMedica, Inc. Common Stock
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrom… Read more
PaxMedica, Inc. Common Stock (PXMD) - Total Assets
Latest total assets as of September 2024: $820.38K USD
Based on the latest financial reports, PaxMedica, Inc. Common Stock (PXMD) holds total assets worth $820.38K USD as of September 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
PaxMedica, Inc. Common Stock - Total Assets Trend (2018–2023)
This chart illustrates how PaxMedica, Inc. Common Stock’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
PaxMedica, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2023)
PaxMedica, Inc. Common Stock's total assets of $820.38K consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 82.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2023)
This chart illustrates how PaxMedica, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: PaxMedica, Inc. Common Stock's current assets represent 100.0% of total assets in 2023, unchanged from 100.0% in 2018.
- Cash Position: Cash and equivalents constituted 82.9% of total assets in 2023, down from 100.0% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
PaxMedica, Inc. Common Stock Competitors by Total Assets
Key competitors of PaxMedica, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
PaxMedica, Inc. Common Stock - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - PaxMedica, Inc. Common Stock generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - PaxMedica, Inc. Common Stock is currently not profitable relative to its asset base.
PaxMedica, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.36 | 0.99 | 1.15 |
| Quick Ratio | 0.36 | 0.99 | 1.15 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-1.43 Million | $ -36.92K | $ 32.69K |
PaxMedica, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between PaxMedica, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.98 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 157.7% |
| Total Assets | $5.68 Million |
| Market Capitalization | $2.17K USD |
Valuation Analysis
Below Book Valuation: The market values PaxMedica, Inc. Common Stock's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: PaxMedica, Inc. Common Stock's assets grew by 157.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for PaxMedica, Inc. Common Stock (2018–2023)
The table below shows the annual total assets of PaxMedica, Inc. Common Stock from 2018 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $5.68 Million | +157.69% |
| 2022-12-31 | $2.20 Million | +239.72% |
| 2021-12-31 | $648.87K | -42.25% |
| 2020-12-31 | $1.12 Million | +4404.05% |
| 2019-12-31 | $24.95K | +167.61% |
| 2018-12-31 | $9.32K | -- |